Fulfilling the promise of advanced analytics in oncology
In oncology we have read the exciting headlines predicting that big data and advanced analytics will transform cancer care and research and that all patients, thanks to machine learning, will soon receive personalized treatment plans. But progress has been arguably slower than initially envisioned.
However, without a doubt, important advances are being made. Researchers have built a model that can accurately predict molecular subtypes in head and neck cancers using radiomics, a machine-learning technique that can help identify, classify, and monitor solid tumors.
Lack of talent is one reason why pharmaceutical companies are not making more progress applying advanced analytics to oncology. Whatever their circumstances, however, all pharmaceutical companies will need a strategy for applying advanced analytics to their work in oncology.